期刊
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2021.757718
关键词
Roseburia; Roseburia intestinalis; probiotic; inflammatory bowel disease (IBD); microbiome
资金
- National Natural Science Foundation of China (NSFC ) [81970494, 81800500]
- [(81800500) 81970494]
Roseburia intestinalis, a bacterium that produces butyrate in the colon, has been shown to play a crucial role in preventing intestinal inflammation and maintaining energy homeostasis. Patients with inflammatory bowel disease may benefit from modulating the abundance of R. intestinalis. Recent advancements in research technologies have revealed the therapeutic potential of this bacterium in human health and disease treatment.
Roseburia intestinalis is an anaerobic, Gram-positive, slightly curved rod-shaped flagellated bacterium that produces butyrate in the colon. R. intestinalis has been shown to prevent intestinal inflammation and maintain energy homeostasis by producing metabolites. Evidence shows that this bacterium contributes to various diseases, such as inflammatory bowel disease, type 2 diabetes mellitus, antiphospholipid syndrome, and atherosclerosis. This review reveals the potential therapeutic role of R. intestinalis in human diseases. Patients with inflammatory bowel disease exhibit significant changes in R. intestinalis abundance, and they may benefit a lot from modulations targeting R. intestinalis. The data reviewed here demonstrate that R. intestinalis plays its role in regulating barrier homeostasis, immune cells, and cytokine release through its metabolite butyrate, flagellin and other. Recent advancements in the application of primary culture technology, culture omics, single-cell sequencing, and metabonomics technology have improved research on Roseburia and revealed the benefits of this bacterium in human health and disease treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据